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Ivy JR, Jones NK, Costello HM, Mansley MK, Peltz TS,
Flatman PW, Bailey MA. Glucocorticoid receptor activation stimu-
lates the sodium-chloride cotransporter and influences the diurnal
rhythm of its phosphorylation. Am J Physiol Renal Physiol 317:
F1536–F1548, 2019. First published October 7, 2019; doi:10.1152/
ajprenal.00372.2019.—The sodium-chloride cotransporter (NCC) in
the distal convoluted tubule contributes importantly to sodium balance
and blood pressure (BP) regulation. NCC phosphorylation determines
transport activity and has a diurnal rhythm influenced by glucocorti-
coids. Disturbing this rhythm induces “nondipping” BP, an abnormal-
ity that increases cardiovascular risk. The receptor through which
glucocorticoids regulate NCC is not known. In this study, we found
that acute administration of corticosterone to male C57BL6 mice
doubled NCC phosphorylation without affecting total NCC abun-
dance in both adrenalectomized and adrenal-intact mice. Corticoste-
rone also increased the whole kidney expression of canonical clock
genes: period circadian protein homolog 1 (Per1), Per2, crypto-
chrome 1, and aryl hydrocarbon receptor nuclear translocator-like
protein 1. In adrenal-intact mice, chronic blockade of glucocorticoid
receptor (GR) with RU486 did not change total NCC but prevented
corticosterone-induced NCC phosphorylation and activation of clock
genes. Blockade of mineralocorticoid receptor (MR) with spironolac-
tone reduced the total pool of NCC but did not affect stimulation by
corticosterone. The diurnal rhythm of NCC phosphorylation, mea-
sured at 6-h intervals, was blunted by chronic GR blockade, and a
similar dampening of diurnal variation was seen in GR heterozygous
null mice. These effects on NCC phosphorylation did not reflect
altered rhythmicity of plasma corticosterone or serum and glucocor-
ticoid-induced kinase 1 activity. Both mineralocorticoids and gluco-
corticoids emerge as regulators of NCC, acting via distinct receptor
pathways. MR activation provides maintenance of the NCC protein
pool; GR activation dynamically regulates NCC phosphorylation and
establishes the diurnal rhythm of NCC activity. This study has
implications for circadian BP homeostasis, particularly in individuals
with abnormal glucocorticoid signaling as is found in chronic stress
and corticosteroid therapy.
blood pressure; circadian rhythm; distal convoluted tubule; glucocor-
ticoid; sodium-chloride cotransporter
INTRODUCTION
The main sodium entry pathway in the distal convoluted
tubule (DCT) is the thiazide-sensitive sodium-chloride cotrans-
porter (NCC). NCC-mediated salt reabsorption contributes
importantly to blood pressure (BP) regulation: null mutations
in the encoding gene, SLC12A3, cause Gitelman’s syndrome,
characterized by urinary salt wasting and low BP; “gain-of-
function” in NCC, arising from mutations in key regulatory
kinases and ubiquitin ligases, causes the hypertensive disorder
of pseudohypoaldosteronism type II (25). NCC activity is
modulated by multiple hormonal systems (41) and also directly
by plasma potassium concentration (37, 47). In addition to
control of NCC abundance per se, hormones and other factors
engage a regulatory cascade of serine/threonine kinases, in-
cluding with-no-lysine kinase (WNK)1 and WNK4, STE20/
SPS1-related proline/alanine-rich kinase, and oxidative stress-
response kinase 1 (2). These kinases influence phosphorylation
at conserved residues in the NH2-terminus, influencing traf-
ficking in the apical membrane of the DCT and establishing
overall NCC activity in vivo. In the mouse, three critical
residues are Thr53, Thr58, and Ser71, with Thr53 phosphoryla-
tion, measured in the current study, increasing membrane
retention and activity of NCC (40, 43).
Circadian transcription factors influence renal function (11)
and BP (12). The DCT expresses the canonical circadian
transcription factors period circadian protein homolog 1
(Per1), Per2, aryl hydrocarbon receptor nuclear translocator-
like protein (Arntl or Bmal1), Clock, and cryptochrome 1/2
(Cry1 and Cry2) (54). In a DCT cell line, Per1 transcriptionally
regulates WNKs and phosphorylation of NCC (39). In humans
(8) and rodents (19, 49), phosphorylated (p)NCC has a marked
diurnal variation, being higher in the active phase and lower in
the inactive, or sleep, phase of the 24-h cycle. Rhythmic
physiology is synchronized to the day/night cycle by the master
clock in the suprachiasmatic nucleus (SCN) of the hypothala-
mus, which itself is entrained by the photoperiod. Glucocorti-
coids (cortisol in humans and corticosterone in rodents) entrain
peripheral clocks, including those in the kidney, to the rhythm
established centrally by the SCN (4, 33). We recently found
that abolishing diurnal variation in circulating glucocorticoid
by adrenalectomy or chronic corticosterone infusion flattened
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the diurnal variation in pNCC and induced nondipping BP
(19). Nondipping, aka nocturnal, hypertension in humans in-
creases cardiovascular risk (45) and precedes and predicts
nephropathy in diabetes (23). In our mouse study, thiazide
partially restored normal diurnal BP variation in corticoste-
rone-treated mice (19).
The receptor through which glucocorticoids regulate NCC
activity is not known. Glucocorticoids have approximately
equal affinity for the glucocorticoid receptor (GR) and the
mineralocorticoid receptor (MR), and DCT cells express both
receptors (1). The distal nephron is conventionally considered
aldosterone sensitive because of high expression of 11-hy-
droxysteroid dehydrogenase type 2 (11HSD2), which metab-
olizes and inactivates cortisol/corticosterone. However, we
(17) and others (7, 28, 34) have shown that the DCT expresses
weak/undetectable levels of 11HSD2, which may be re-
stricted to the short DCT2 segment. We therefore proposed that
glucocorticoids can activate MR to increase pNCC. To test this
hypothesis, we chronically treated mice with either spironolac-
tone, a MR antagonist, or RU486, a GR antagonist, and
assessed the effect of acute administration of corticosterone on
pNCC. In a separate experiment, the effect of RU486 on the
diurnal variation of NCC phosphorylation was measured.
METHODS
Animals. Male C57BL6J/Ola mice (Harlan) were used for experi-
ments 1–3. Male mice haploinsufficient for the GR (GRgeo/, as
described in Refs. 18 and 27) and their wild-type littermates (GR/)
were used for experiment 4. Mice were between 2 and 4 mo of age and
were acclimatized to a 12:12-h light-dark cycle for at least 2 wk
before experiments and given free access to water and standard chow
(maintenance diet 1; Special Diet Services, Essex, UK). The lights
were turned on at 7:00 AM local time, and this was defined as
Zeitgeber time 0 (ZT0); lights were turned off at 7:00 PM (ZT12). All
experiments were performed in accordance with the United King-
dom’s Animals (Scientific Procedures) Act of 1986 and under the
authority of a project license issued by the United Kingdom Home
Office following approval by the University’s Animal Welfare &
Ethical Review Board.
Tissue collection. Mice were terminated by cervical dislocation
within 1 min of removal from the holding room. A laparotomy was
performed, and the kidneys were removed, decapsulated, snap frozen
on dry ice, and stored at 80°C for Western blot analysis and
quantitative PCR (qPCR) analysis. A terminal plasma sample was
taken via the abdominal vena cava and used to measure plasma
corticosterone in some experiments.
Plasma corticosterone. Plasma corticosterone was measured using
a commercially available corticosterone EIA kit (Enzo Life Sciences).
All reagents were provided in the kit. Plasma corticosterone was
extracted from plasma samples by incubating 10 L of sample with
10 L of steroid displacement reagent [SDR; diluted 1:100 with assay
buffer 15 (AB15)] for 5 min at room temperature (RT) in sterile glass
tubes. AB15 (280 L) was then added along with 3 mL ethyl acetate
(Sigma-Aldrich), and the glass tube was vortexed thoroughly, incu-
bated (RT, 2 min), and vortexed again. The clear organic upper layer
was aspirated to a new glass tube. The samples were desiccated under
nitrogen at 60°C. Standards and samples were prepared in duplicate
and assayed according to the manufacturer’s instructions. Absorbance
measurements (405 nm and corrected with 580 nm) were plotted
against the known standard values using GraphPad software, the r2
value for the sigmoidal curve produced was 0.98, and the concen-
trations of the unknown samples were interpolated on the line.
Plasma electrolyte measurements. Plasma potassium and sodium
were measured in two parallel cohorts of animals: first, in mice
acutely injected with corticosterone (n  10) or vehicle (n  9) and,
second, in mice treated for 5 days with RU486 (n 3) or vehicle (n
4). To avoid hemolysis, blood was drawn from an arterial line
under general anesthesia, induced by intraperitoneal injection of
100 mg/kg thiopentalbarbitol. The carotid artery was cannulated
using PE-10 tubing containing 20 U/L porcine heparin saline
Table 1. Quantitative RT-PCR assay details
Gene Description (Protein Abbreviation) Forward Primer (5= to 3=) Reverse Primer (5= to 3=) Probe, bp
Rn18s 18S rRNA ctcaacacgggaaacctcac cgctccaccaactaagaacg 77
Tbp TATA box-binding protein (TBP) gggagaatcatggaccagaa gatgggaattccaggagtca 97
Hprt1 Hypoxanthine-guanine phosphoribosyltransferase
(HPRT)
cctcctcagaccgcttttt aacctggttcatcatcgctaa 95
Per1 Period circadian protein homolog 1 (PER1) gcttcgtggacttgacacct tgctttagatcggcagtggt 71
Per2 Period circadian protein homolog 2 (PER2) gcttcgtggacttgacacct tgctttagatcggcagtggt 5
Clock-201 Circadian locomotor output cycles protein kaput
(CLOCK)
ccagtcagttggtccatcatt tggctcctaactgagctgaaa 76
Cry1 Cryptochrome 1 (CRY1) ggcagagcagtaactgatacga tgactttcccaccaacttca 52
Cry2 Cryptochrome 2 (CRY2) ggagcatcagcaacacagg ccgcttggtcagttcttcac 11
Arnt1 var1 Aryl hydrocarbon receptor nuclear translocator-like
protein 1 (BMAL1)
gaatacattgtctcaaccaacactg ttagctgcgggaaggttg 97
Nr1d1 Nuclear receptor subfamily 1 group D
member 1 (Rev-erb)
cgaccctggactccaataac tgccattggagctgtcact 52
Nr1d2 Nuclear receptor subfamily 1 group D
member 2 (Rev-erb)
stggagctgaacgcagga tcagaaccctcactgtgacaa 16
Sgk1 Serum- and glucocorticoid-induced
kinase 1 (SGK1)
gattgccagcaacacctatg ttgatttgttgagagggacttg 91
Tsc22d3 v2 Glucocorticoid-induced leucine zipper
protein (GILZ)
tccgttaaactggataacagtgc tggttcttcacgaggtccat 49
Nr3c2 Mineralocorticoid receptor (MR) caaaagagccgtggaagg tttctccgaatcttatcaataatgc 11
Nr3c1 Glucocorticoid receptor (GR) tgacgtgtggaagctgtaaagt catttcttccagcacaaaggt 56
Hsd11b2 11-Hydroxysteroid dehydrogenase
type 2 (11HSD2)
cactcgaggggacgtattgt gcaggggtatggcatgtct 26
Slc12a3 Sodium-chloride cotransporter (NCC) cctccatcaccaactcacct ccgcccacttgctgtagta 12
Wnk4 With-no-lysine kinase 4 (WNK4) tccgatttgatctggatgg gggcaggatgaactcattgta 26
Assays were designed using the Roche Universal Probe library, and assays were run using Roche Universal Probe library probes.
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(Sigma-Aldrich). After the heparin saline had been cleared from
the tubing, an ~500-L sample of arterial blood was collected in
lithium/heparin-coated tubes, and plasma was separated by centrif-
ugation. Plasma electrolytes were measured using an electrolyte
analyzer (Roche).
Immunoblot analysis. Western blots were performed on homoge-
nized whole kidney samples as we have described (17) using primary
antibodies against NCC (Chemicon) and pThr53-NCC. We have
previously reported that pThr53-NCC abundance had a marked diurnal
variation (19). Images were developed by electrochemiluminescence
and quantified by densitometry using ImageJ, as described (26).
Coomassie blue staining was adapted for use as a loading control to
normalize the immunoblot results for the amount of protein loaded on
the gel. A dose curve indicated that densitometry of the Coomassie
blue staining was linear in the range of 10–40 g protein. The bottom
of the gel, just above the 55-kDa mark, was trimmed and incubated in
Coomassie blue solution (RT, 3–4 h) and then destaining solution
overnight. For occasions where two or more Western blots were
required to run the samples, these were run contemporaneously using
the same conditions, and a reference load was prepared from a pool of
homogenate run on each gel to normalize the data to account for
interrun differences.
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Fig. 1. Adrenalectomy reduces total levels of the sodium-chloride cotransporter (NCC, A). In adrenalectomized animals, acute corticosterone injection induced
an upregulation of NCC phosphorylation at Thr53 (B), accompanied by changes in gene expression (C). C57BL6 mice were adrenalectomized [vehicle
(Veh)/corticosterone (Cort)] or undisturbed (In), and all were maintained on 0.9% saline in place of drinking water. Mice then received an acute intraperitoneal
injection of vehicle (Veh/Intact) or corticosterone, and kidneys were taken 6 h later for Western blot analysis. All samples were run on the same blots or evenly
distributed across blots and normalized to a reference lane. All rearrangements of blots are for clarity. Signal densities for immunoblots were normalized to
Coomassie signal densities and to the reference lane (R) and were analyzed by one-way ANOVA, followed by post hoc Tukey’s tests (n 8 biological replicates,
A), t-tests (n  10, B), or two-way ANOVA followed by post hoc Sidak’s tests (n  10, C). Data are means 	 SD. See Table 1 for gene descriptions and protein
names.
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Quantitative PCR. RNA was extracted from half kidneys using
RNeasy spin columns (QIAGEN), and the RNA concentration was
quantified using a Nanodrop 1000 spectrophotometer. RNA concen-
trations were 200–700 ng/L. All samples taken forward for reverse
transcription had ratios of absorbance at 260 to 280 nm of 1.7–2.1.
The absorbance ratios of 260 to 230 nm were usually in the range of
1.8–2.2. Reverse transcription was carried out on 500 ng RNA using
the AB High Capacity RT Kit (Life Technologies). Included in each
RT-PCR round were a no-template control and a no-reverse transcrip-
tase control. Resultant cDNA samples were stored at 20°C before
dilution for qRT-PCR. Assays for qPCR were designed using the
Roche Universal Probe library so that the amplicon spanned an
intron excluding the first or last intron to avoid targeting any
single-nucleotide polymorphisms. Primers were then screened
through the Integrated DNA technologies oligo analyzer tool
(http://www.idtdna.com/calc/analyzer) to identify those with any
hairpins, self-dimers, and heterodimers. All selected primers were
purchased from Eurofins Scientific. Each assay was quality controlled
and rejected if the standard curve error exceeded 0.05 (i.e., the mean
squared error of the data points making up the standard curve) or the
efficiency was outside the range of 1.7–2.1. PCR products were also
examined with loading dye (DNA Gel Loading Dye, 6X; Life Tech-
nologies) on a 4% Tris-borate-EDTA agarose gel with 0.05%
ethidium bromide to ensure the amplicons conformed to the expected
lengths. Primers and probe combinations are given in Table 1. TATA
box-binding protein (TBP), hypoxanthine-guanine phosphoribosyl-
transferase (HPRT), and 18S rRNA were used as endogenous control
genes.
qPCR Quantification. Quantitation was achieved using the auto-
mated LightCycler 480 software, which identifies the threshold cycle
(CT) value for each well by finding the maximum value from a plot of
second derivative of fluorescence versus time. Each triplicate value
was analyzed, and replicates were excluded if the CT SD was 0.5.
Results were accepted if the standard curve was adequate, as assessed
by efficiency within the range of 1.7–2.1 and error 
0.05 (i.e., the
mean squared error of the data points making up the standard curve).
Endogenous control genes were used to normalize the experimental
gene values. A panel of three endogenous control genes was used,
including TBP, HPRT, and 18S rRNA (15, 32, 46). The expression of
these control genes did not differ across any of the experimental
groups, and CT values were ~25–33, 22–28, and 7–15 for TBP,
HPRT, and 18S, respectively. Test gene CT values ranged from 22 to
37. The level of endogenous control genes was normalized such that
the control sample was equal to one (so as not to give greater weight
to any one of the control genes), and the mean of all three control
genes was taken. The experimental gene expression was then calcu-
lated as the mean level normalized to the mean of the control genes
and log10 transformed to normalize the spread of data.
Experiment 1: acute corticosterone administration in adrenalecto-
mized mice. Bilateral adrenalectomy was performed under isofluorane
anesthesia and buprenorphine (0.1 mg/kg sc Vetergesic) analgesia.
After recovery, adrenalectomized (ADX) and control mice were
individually housed and given ad libitum access to 0.9% saline and tap
water. An “adrenal-intact” group (n  8) was anesthetized but not
surgically manipulated. At postoperative day 9, ADX animals were
injected subcutaneously at ZT1 with either vehicle (2% DMSO in
0.9% sterile injectable saline, n  8) or 6 mg/kg corticosterone (n 
10). Mice were terminated at ZT5, and kidneys were taken. Adrenal-
intact animals (n  10) were not injected but terminated at the same
time as ADX animals.
Experiment 2: acute corticosterone treatment with chronic MR or
GR blockade in adrenal-intact mice. Elastomer pellets were used to
encapsulate spironolactone (MR antagonist) or RU486 (GR antagonist)
for slow release as previously described (3). Pellets contained ~30 mg of
drug, and, in vitro, the release rate was ~3 mg·kg1·day1. In each
mouse, two pellets were implanted subcutaneously under isofluorane
anesthesia and buprenorphine analgesia (0.1 mg/kg sc Vetergesic).
Groups were as follows: spironolactone, RU-486, or blank. After 5 days,
mice from each of these three treatment groups were then injected at ZT0
with either vehicle or 6 mg/kg corticosterone (sc). Mice were terminated
at ZT4, and kidneys were taken for analysis.
Experiment 3: RU486 and the diurnal variation of NCC
phosphorylation. Mice were treated for 5 days with 60 mg RU486 or
no-drug pellet and terminated for tissue collection (as above) at ZT0,
ZT6, ZT12, and ZT18. Mice were pair housed with one treated with
RU-486 and the other with vehicle and terminated contemporaneously
for tissue collection (as above) at ZT6 and ZT18.
Experiment 4: GR heterozygotes and diurnal variation of NCC
phosphorylation. GRgeo/ and GR/ mice were pair housed and
terminated in pairs together for tissue collection (as above) at ZT6 and
ZT18.
Statistical analysis. Data are presented as individual points with
group means	 SD. The number of biological replicates (n) for each
experimental group is given in the figures along with the test used for
statistical analysis. Data were analyzed by t-tests or, where there was
more than one dependent factor, two-way ANOVA with post hoc
Sidak’s tests.
RESULTS
Corticosterone increases NCC phosphorylation in ADX rats.
Following bilateral adrenalectomy (5 days), total NCC abun-
dance was significantly reduced in ADX mice compared with
adrenal-intact mice (Fig. 1A). ADX mice were injected intra-
peritoneally with a bolus of either corticosterone or vehicle at
ZT0. Kidneys were taken at ZT4, and the abundance of
pT53-NCC, measured by Western blot, was approximately
twofold higher in corticosterone-injected mice compared with
vehicle controls (Fig. 1B). There was no difference in mRNA
abundance for the NCC encoding gene, Slc12a3 (Fig. 1C).
Acute corticosterone did, however, increase the whole kidney
mRNA expression of serum- and glucocorticoid-induced ki-
nase 1 (Sgk1) and the gene encoding glucocorticoid-induced
leucine zipper protein (GILZ, Fig. 1C). The expression of
clock genes Arntl1, Cry1, Per1, and Per2 was significantly
increased by acute administration of corticosterone to ADX
mice (Fig. 1C). Plasma potassium concentration, an important
regulator of NCC phosphorylation, was measured in parallel
groups of mice and found to be lower in corticosterone-treated
mice (P  0.06, Table 2).
Table 2. Plasma sodium and potassium from C57BL6 mice treated acutely with corticosterone (6 mg/kg sc) or chronically
for 5 days with RU486 versus control
Treatment Group Plasma Sodium, mmol/L P Value (Plasma Sodium) Plasma Potassium, mmol/L P Value (Plasma Potassium) n
Acute vehicle 143.5	 2.2 0.87 4.05	 0.3 0.06 10
Acute Corticosterone 143.3	 2.2 3.81	 0.2 9
Control 146.3	 2.6 0.34 4.25	 0.3 0.10 4
Chronic RU486 148.3	 2.5 3.80	 0.2 3
Data are means 	 SD and were analyzed by Student’s t-tests; n, no. of biological replicates.
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Chronic GR antagonism prevents acute phosphorylation of
NCC by corticosterone. To resolve the receptor pathways
through which corticosterone activated NCC, we used ad-
renal-intact mice pretreated with either spironolactone (MR
antagonist) or RU486 (GR antagonist). Control mice were
implanted with a no-drug pellet. Chronic MR blockade by
spironolactone significantly reduced total NCC abundance
compared with the no-drug group, but total NCC was
unchanged in RU486-treated animals (Fig. 2A). Acute in-
jection of corticosterone at ZT0, the nadir of the endogenous
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Fig. 2. In adrenal-intact mice, sodium-chloride
cotransporter (NCC) total protein is reduced by min-
eralocorticoid receptor (MR) but not glucocorticoid
receptor (GR) antagonism; however, GR antagonism
prevents corticosterone (Cort)-induced NCC phos-
phorylation at Thr53 (T53). A: NCC protein was
measured in whole kidney homogenate taken from
mice treated for 5 days with a slow-release Silastic
pellet containing spironolactone (Spiro, 50 mg),
RU486 (60 mg), and in controls (no-drug pellet).
NCC phosphorylation at threonine (pT53) was mea-
sured in whole kidney homogenate taken from un-
treated mice (no drug, B), 5-day spironolactone-
treated (50 mg, C), and 5-day RU486-treated (D)
mice, 4 h following acute corticosterone administra-
tion. Samples were run on the same blots (B–D) or
evenly distributed across blots and normalized to a
reference lane (A). All rearrangements of blots are
for clarity. Signal densities for immunoblots were
normalized to Coomassie signal densities. Veh,
vehicle. Data are means 	 SD and were analyzed
by one-way ANOVA (A) and Student’s t-tests
(B–D), n  6 biological replicates.
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Fig. 3. Gene expression in C57BL6 mouse kidneys in response to 5-day vehicle (black circles), chronic spironolactone (Spiro, 50 mg, white squares), or chronic
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corticosterone rhythm, significantly increased pT53-NCC in
the no-drug controls (Fig. 2B) and in the mice pretreated
with spironolactone (Fig. 2C). In contrast, acute corticoste-
rone did not increase pT53-NCC in mice chronically treated
with RU486 (Fig. 2D). Notably, plasma potassium tended to
be lower in RU486-treated mice (Table 2).
We again profiled whole kidney mRNA expression of a
panel of genes known to influence NCC expression. Neither
chronic spironolactone nor RU486 affected the expression of
Nr3c1 (encoding GR; Fig. 3A), Nr3c2 (encoding MR; Fig. 4B),
Hsd11b2 (encoding 11HSD2; Fig. 4C), or Slc12a3 (encoding
NCC; Fig. 3D). Acute administration of corticosterone did not
change mRNA abundance of these genes. We again found that
acute corticosterone significantly increased the expression of
Sgk1 (Fig. 3F) and Tsc22d3 (encoding GILZ; Fig. 3G). The
effect on Sgk1 was significantly blunted both by MR and GR
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antagonism; the stimulatory effect on Tsc22d3 persisted during
chronic MR and GR blockade.
Chronic GR antagonism blunts the diurnal variation in NCC
phosphorylation. pT53-NCC has a diurnal rhythm that is influ-
enced by plasma corticosterone (19). Therefore, we next assessed
the effect of RU486 pretreatment on pT53-NCC measured at 6-h
intervals through the 24-h cycle. In untreated mice, implanted
with a no-drug pellet, pT53-NCC showed a marked diurnal
variation and was higher at ZT12 and ZT18 than at ZT0 and ZT
(Fig. 4, A and B). In RU486-treated mice, pT53-NCC was higher
at ZT0 and ZT6 than in no-drug controls; this significantly blunted
the diurnal variation in pT53-NCC abundance (Fig. 4, A and C).
Surprisingly, only Per1 and Nr1d1 expression was altered by
chronic RU486 treatment; the rhythm of other clock genes re-
mained intact (Fig. 5). We also assessed the activity of SGK1 at
each time point, using the phosphorylation of n-myc downstream
regulated kinase 1 (NDRG1) as a surrogate. NDRG1 is phosphor-
ylated by SGK1 but not by other closely related kinases and
therefore can be used as a measure of endogenous SGK1 activity
(24). SGK1 activity displayed a marked diurnal variation, being
higher in subjective night; this was not affected by chronic RU486
treatment (Fig. 6).
In a final series of experiments, we assessed diurnal pT53-
NCC abundance in mice heterozygous for a null mutation in
Nr3c1, encoding GR. Using archived protein homogenates of
kidney tissue taken at ZT6 and ZT18, we found no difference in
total NCC abundance between genotypes (Fig. 7A). However, the
significant diurnal variation in pT53-NCC seen in wild-type mice
was lost in GR heterozygote null animals (Fig. 7B).
DISCUSSION
Our study aimed to determine the receptor pathway through
which glucocorticoids regulate NCC activity and had three
main findings. First, adrenal hormones influence the total pool
of NCC protein available for phosphorylation via tonic activa-
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tion of MR. Second, corticosterone activates the phosphoryla-
tion of NCC via GR but not MR. Third, GR activation,
presumably by corticosterone, contributes to the diurnal vari-
ation of NCC phosphorylation, itself a regulator of the circa-
dian rhythm of BP.
MR activation regulates the total NCC pool. Bilateral adre-
nalectomy or chronic spironolactone treatment of adrenal-
intact mice reduced the abundance of total NCC protein, and
the effects were of similar magnitude. Previous studies found
that chronic spironolactone treatment reduced NCC by ~40%
in adrenal-intact rats (30), and selective renal tubular deletion
of MR exerts a similar effect on NCC abundance in adrenal-
intact mice (50). Furthermore, aldosterone infusion in rats
causes an MR-dependent increase in NCC abundance (20, 29,
52) and also enhances NCC expression in ADX animals (30,
53), although NCC abundance is not normalized (9). Similar
data are reported in mice, and here the stimulatory effect of
aldosterone on NCC abundance appears to be restricted to
DCT2 cells (34).
The contribution of glucocorticoid/GR signaling to total
NCC abundance is less clear. In our study, chronic RU486
treatment did not alter total NCC expression. In contrast to this,
chronic dexamethasone increased [3H]metolazone binding
density (reflecting NCC transporter number) and thiazide-
sensitive sodium transport in vivo (reflecting transporter activ-
ity) in ADX rats (9, 53). The stimulatory effect of GR agonism
was additive to aldosterone (9), suggesting that distinct recep-
tor pathways contribute to the overall regulation of the NCC
pool by adrenal steroids. However, other studies have sug-
gested that dexamethasone, in contrast to aldosterone, cannot
restore NCC expression in ADX rats (29). Overall, multiple
studies in rodents have shown that aldosterone/MR signaling
plays an important role in determining the amount of NCC
expressed in DCT cells; the effect of glucocorticoids/GR is
currently less clearly defined.
GR activation promotes NCC phosphorylation. We found
that NCC phosphorylation at key residues was directly affected
by manipulation of in vivo glucocorticoid status (19). We now
show that glucocorticoids directly increase phosphorylation of
NCC at Thr53, used widely as a surrogate for in vivo NCC
activity since it promotes membrane retention of the trans-
porter (40, 43). Surprisingly, chronic spironolactone pretreat-
ment did not prevent corticosterone-induced pT53-NCC, and
we therefore discount glucocorticoid activation of MR. Instead,
RU486 (aka mifepristone) pretreatment completely prevented
phosphorylation of NCC by corticosterone. RU486 is a steroi-
dal antagonist of GR with greater binding affinity than the
endogenous glucocorticoid. It does not bind to MR but is an
effective antagonist of both the progesterone receptor (6) and
the androgen receptor (14). We do not consider that androgen
receptor inhibition is an important factor in the current study,
since previous work has shown that orchiectomy did not affect
pNCC or total protein levels (16). The progesterone receptor,
expressed in male kidney (36), is likely to be fully antagonized
by our RU486 pretreatment protocol. Moreover, circulating
progesterone in male mice originates from the adrenal gland,
and adrenalectomy would therefore abolish progesterone pro-
duction in our experiments. This may be relevant to our current
findings. Progesterone increases NCC abundance/phosphory-
lation in female rodents (42) and accounts for the sexual
dimorphism of elevated NCC activation in female rodents.
Whether progesterone contributes significantly to NCC activa-
tion in male animals is less clear. Progesterone is typically low
in male animals and also lacks a circadian rhythm (16).
Overall, we cannot exclude a role for either the progesterone or
androgen receptor, but the most plausible explanation of our
data is that corticosterone induces phosphorylation of NCC via
activation of GR.
We do not yet know the molecular mechanism connecting
GR activation to NCC phosphorylation, but it is unlikely to
involve SGK1; corticosterone injection increased whole kidney
SGK1 abundance, which was prevented by pretreatment with
either MR or GR antagonists. Plasma potassium concentration
is recognized as a major regulator of NCC, with hypokalemia
inducing phosphorylation of the transporter (37, 47). In pa-
tients with Cushing syndrome, phosphorylation of NCC in
urinary exosomes correlated with serum potassium rather than
urinary free cortisol (44). In our study, plasma potassium
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tended to be lower in mice receiving corticosterone, but plasma
potassium was not altered by RU486 pretreatment, and we do
not think this was a major factor in our study (Table 2). We did
not measure plasma potassium in mice treated with spirono-
lactone, but MR antagonism is widely recognized as inducing
hyperkalemia, which in turn dephosphorylates NCC (37, 47).
Mice with kidney-specific deletion of the -epithelial sodium
channel subunit are severely hyperkalemic and show reduced
NCC expression (5). Prevention of hyperkalemia through di-
etary potassium restriction and/or treatment with a potassium
binder restored NCC abundance to control levels, suggesting
that plasma potassium is a primary regulator of the NCC pool.
Thus, MR blockade did not prevent phosphorylation of NCC
by acute corticosterone in our experiments, but spironolactone-
induced hyperkalemia could account for the observed reduc-
tion in total NCC protein.
Drawing consensus from our study and the literature, both
aldosterone and corticosterone influence NCC activity via their
cognate receptors. At a molecular level, it is unclear how the
DCT cell discriminates between glucocorticoid/GR and aldo-
sterone/MR signaling. Cells in DCT1 and DCT2 express both
receptors (1), and expression of the glucocorticoid-metaboliz-
ing enzyme 11HSD2 may be restricted to DCT2 or may even
be absent altogether in the mouse. Thus, DCT cells are not
uniformly configured as conventional “aldosterone-target”
cells, and alternative processes may be in play. It is possible,
for example, that MR can discriminate between aldosterone
and glucocorticoid in the absence of 11HSD2 (22). Recent
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research has shown that G protein-coupled receptor 30, the
membrane receptor accounting for the rapid nongenomic ac-
tions of estrogen (35), is also important for rapid plasma
potassium-dependent activation of NCC by aldosterone (10).
Certainly, pathways of adrenal steroid signaling in the DCT are
not resolved and cannot be explained by classical definitions.
The GR in the diurnal rhythm of pNCC. We confirmed the
diurnal rhythm of pNCC (19, 49), further finding that chronic
systemic GR antagonism perturbed this rhythm. This prompted
assessment of diurnal variation in pNCC in mice with a
genetically induced reduction in GR expression (18, 27). We
were only able to assess pNCC in GR heterozygote null mice
at two time points using archived kidney protein homogenates,
the midpoints of the subjective day and night, but our data
indicate that reduced GR expression significantly dampened
the pNCC phosphorylation rhythm. This complements our
previous work in which we introduced arrhythmicity of plasma
corticosterone, either by adrenalectomy or by pharmacological
clamping in the midphysiological range (19). Overall, these
two studies show that impairment of dynamic GR signaling
suppresses pNCC rhythmicity. The effect of MR blockade was
not assessed here because our previous work indicated that
aldosterone was not a major regulator of pNCC rhythmicity
(19). Nevertheless, others have shown that chronic eplerenone
treatment dampened pNCC rhythm (49), and we cannot there-
fore exclude a role of aldosterone/MR signaling.
The molecular mechanisms through which GR contributes to
pNCC rhythm are not clear. It is probable that GR engages
with the DCT clock since glucocorticoids have a major role in
synchronizing peripheral clocks to the master clock in the SCN
(4, 33). It is also probable that the DCT clock integrates with
NCC regulatory pathways at some level, since Per1 and Bmal
null mice demonstrate altered NCC expression (13, 51). More-
over, clock genes may regulate NCC by acting as transcription
factors to genes within the NCC regulation pathways. Indeed,
both WNK4 and WNK1 contain E-box-binding sites, interac-
tion sites for Per1 and Cry1 (39). Blocking the nuclear entry of
Per1 in vitro decreased NCC activity through transcriptional
regulation of NCC, WNK1, KS-WNK1, and WNK4 (39). We
therefore profiled clock gene expression in our glucocorticoid
manipulation experiments. In ADX mice, corticosterone ro-
bustly increased the expression of Per1, Per2, Cry1, and Bmal.
In adrenal-intact mice, corticosterone increased only Per1 and
Per2 expression 4 h posttreatment, and this effect was blocked
by either MR or GR inhibition. When assessed at 6-h intervals,
all clock genes displayed robust rhythms, and, surprisingly,
these were not greatly altered by GR blockade. One interpre-
tation is that kidney clocks are intrinsic and autonomous;
whereas they can be entrained by GC stimulation, they do not
require stimulation to cycle. Consistent with this idea, clock
protein rhythms are maintained in ADX rats (48), and liver-
specific GR ablation did not alter baseline clock rhythms in the
liver (21). Chronic RU486 abolished the pNCC rhythm, sug-
gesting that this operates independent of the DCT clock.
Tubule-specific Bmal knockout mice have no sodium-handling
defects, suggesting that the tubular rhythms may be imposed
by external cues (31). An alternative explanation is that even
small changes in Per1 rhythm affect the pNCC rhythm; in
distal nephron-specific Per1 knockout mice, NCC expression
was increased (13), and Per1 has been shown to interact with
NCC-regulatory pathways (39). It is difficult from our exper-
iments to draw strong conclusions about clock operation in the
DCT. Measurement of mRNA expression at the whole kidney
level lacks refinement, and microarray experiments performed
on isolated segments of DCT/connecting tubule and cortical
collecting duct show clear segmental differences in both the
number of genes that oscillate over a 24-h period and in the
temporal distribution of the acrophases of those genes (54).
This is an important limitation of our study, and operation of
the DCT clock in vivo remains mysterious.
In conclusion, our study demonstrates that glucocorticoids,
acting via GR, are regulators of NCC activity and contribute to
defining activity over the 24-h cycle. Because NCC contributes
importantly to sodium and potassium homeostasis, and BP
control, our findings are relevant to the increased cardiovascu-
lar risk associated with human conditions of glucocorticoid
excess or impaired diurnal rhythmicity in circulating cortisol.
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